Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.80
(
-1.84%
)
Bitcoin
74,085.76
(
0.19%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 88806

Sunday, 01/10/2010 8:20:35 PM

Sunday, January 10, 2010 8:20:35 PM

Post# of 257253
(ABT/ANDS/BMY/IDIX/VRUS) Addendum re today’s VRTX PR:

Based on VRTX’s newfound interest in keeping the VX-222 DDI and monotherapy data under wraps, one could infer that the VX-222 data are less than stellar. If true, this is bullish for such companies as ABT, ANDS, BMY, IDIX, and VRUS, who have early-stage HCV nukes and non-nukes in their pipelines.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now